On September 30, METIS TECHBIO-P rose 5.69% in regular trading, trading at HKD 16.88 per share, with turnover of approximately HKD 53.54 million.

The rally was driven by a confluence of positive catalysts. The company recently disclosed its interim results, reporting first-half revenue of approximately RMB 154 million, surging 13,399% year-over-year and exceeding full-year revenue by 47%. Adjusted net loss narrowed 56.4% to approximately RMB 51.1 million. The core NanoForge platform entered a concentrated commercialization phase, with the OpenCGT project's potential total transaction value surpassing RMB 6 billion.

Additionally, METIS TECHBIO-P was formally included in the Stock Connect program in early September, unlocking southbound capital access. The company also signed strategic partnerships with Green Leaf Pharma and Joinn Biologics, while AI-driven drug development was incorporated as a key priority in the national pharmaceutical industry five-year plan, creating sustained multi-factor momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)